Search

Search Constraints

You searched for: Author/Creator Awad, Mark M

Search Results

1. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Issue 6 (June 2020)

3. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. Issue 2 (16th February 2022)

5. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Issue 2 (February 2022)

6. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. Issue 2 (5th October 2020)

7. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. Issue 2 (5th October 2020)

8. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. Issue 2 (5th October 2020)

9. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. Issue 2 (5th October 2020)